logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Eli Lilly and Company completes $3.2 Billion Acquisition of Morphic Holding, Boosting Its IBD Pipeline

Aug 28, 2024•over 1 year ago

Acquiring Company

Eli Lilly

Acquired Company

Morphic Therapeutic

IndianapolisWalthamManufacturingHealth CareBiopharmaTherapeuticsBiotechnology

Description

Eli Lilly and Company has successfully completed the acquisition of Morphic Holding, a biopharmaceutical company specializing in oral integrin therapies for serious chronic diseases. This strategic acquisition significantly strengthens Lilly’s immunology pipeline, adding Morphic’s promising drug candidate, MORF-057, in development for treating inflammatory bowel disease (IBD).

Company Information

Company

Eli Lilly

Location

Indianapolis, Indiana, United States

About

Eli Lilly is a global healthcare and pharmaceutical company focused on the discovery, development, and delivery of innovative pharmaceutical medicines, vaccines, and consumer healthcare products. It has a strong presence in the diabetes and obesity market segment and has been actively expanding its manufacturing network to meet the increasing demand for its medicines.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed